Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs

Sabrina Chiloiro, Antonella Giampietro, Stefano Frara, Chiara Bima, Federico Donfrancesco, Cara Maya Fleseriu, Alfredo Pontecorvi, Andrea Giustina, Maria Fleseriu, Laura De Marinis, Antonio Bianchi

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Purpose: Osteopathy is an emerging complication of acromegaly. In somatostatin receptor ligands (SRL)-resistant patients, pegvisomant (PegV) and pasireotide LAR (Pasi) are used for acromegaly treatment, but their effect on skeletal health is still not defined. Methods: In a longitudinal retrospective international study, we evaluated incidence of radiological vertebral fractures (VFs) in 55 patients with acromegaly resistant to first-generation SRL. Results: At study entry, prevalent VFs occurred in 23 patients (41.8%). Biochemical acromegaly control was reached in 66.7% of patients on PegV and in 66.7% of patients on Pasi. During the follow-up, incident VFs (iVFs) were detected in 16 patients (29.1%). Occurrence of iVFs was associated with prevalent VFs (P =. 002), persistence of active acromegaly (P =. 01) and higher value of insulin-like growth factor 1 (IGF-1) during follow-up (P =. 03). Among patients with active disease at last visit, iVFs occurred less frequently in patients on treatment with Pasi (25%) compared to PegV (77.8% P =. 04), independently of the IGF-1 values (P =. 90). In patients who reached biochemical control, 22.7% on PegV and 12.5% on Pasi had iVFs (P =. 40). Among both treatment groups, the presence of pre-existent VFs was the main determinant for iVFs. Conclusion: Our data show for the first time that patients with biochemically active disease treated with Pasi had lower risk of iVFs versus those treated with PegV. It also confirms that the presence of pre-existent VFs was the main determinant for iVFs. Additional studies on larger populations and with longer follow-up are needed to confirm our data and disclose the mechanisms underlying our findings.

Original languageEnglish (US)
Article numberdgz054
JournalJournal of Clinical Endocrinology and Metabolism
Volume105
Issue number3
DOIs
StatePublished - Jan 8 2020

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs'. Together they form a unique fingerprint.

Cite this